142 related articles for article (PubMed ID: 28476787)
21. p53 alterations in uterine leiomyosarcomas versus leiomyomas.
de Vos S; Wilczynski SP; Fleischhacker M; Koeffler P
Gynecol Oncol; 1994 Aug; 54(2):205-8. PubMed ID: 8063247
[TBL] [Abstract][Full Text] [Related]
22. Allelic loss at TP53 is not related to p53 protein overexpression in primary human endometrial carcinomas.
Semczuk A; Marzec B; Skomra D; Roessner A; Cybulski M; Rechberger T; Schneider-Stock R
Oncology; 2005; 69(4):317-25. PubMed ID: 16293976
[TBL] [Abstract][Full Text] [Related]
23. MED12 exon 2 mutations in uterine and extrauterine smooth muscle tumors.
Schwetye KE; Pfeifer JD; Duncavage EJ
Hum Pathol; 2014 Jan; 45(1):65-70. PubMed ID: 24196187
[TBL] [Abstract][Full Text] [Related]
24. Leiomyosarcoma of the uterus: A clinicopathologic, DNA flow cytometric, p53, and mdm-2 analysis of 49 cases.
Blom R; Guerrieri C; Stâl O; Malmström H; Simonsen E
Gynecol Oncol; 1998 Jan; 68(1):54-61. PubMed ID: 9454661
[TBL] [Abstract][Full Text] [Related]
25. Genomic alterations in uterine leiomyosarcomas: potential markers for clinical diagnosis and prognosis.
Hu J; Khanna V; Jones M; Surti U
Genes Chromosomes Cancer; 2001 Jun; 31(2):117-24. PubMed ID: 11319799
[TBL] [Abstract][Full Text] [Related]
26. Integrated genome analysis of uterine leiomyosarcoma to identify novel driver genes and targetable pathways.
Cuppens T; Moisse M; Depreeuw J; Annibali D; Colas E; Gil-Moreno A; Huvila J; Carpén O; Zikán M; Matias-Guiu X; Moerman P; Croce S; Lambrechts D; Amant F
Int J Cancer; 2018 Mar; 142(6):1230-1243. PubMed ID: 29063609
[TBL] [Abstract][Full Text] [Related]
27. HPV51-associated Leiomyosarcoma: A Novel Class of TP53/RB1-Wildtype Tumor With Predilection for the Female Lower Reproductive Tract.
Williams EA; Montesion M; Lincoln V; Tse JY; Hiemenz MC; Mata DA; Shah BB; Shoroye A; Alexander BM; Werth AJ; Foley-Peres K; Milante RR; Ross JS; Ramkissoon SH; Williams KJ; Adhikari LJ; Zuna RE; LeBoit PE; Lin DI; Elvin JA
Am J Surg Pathol; 2022 Jun; 46(6):729-741. PubMed ID: 35034043
[TBL] [Abstract][Full Text] [Related]
28. Retained heterodisomy is associated with high gene expression in hyperhaploid inflammatory leiomyosarcoma.
Nord KH; Paulsson K; Veerla S; Wejde J; Brosjö O; Mandahl N; Mertens F
Neoplasia; 2012 Sep; 14(9):807-12. PubMed ID: 23019412
[TBL] [Abstract][Full Text] [Related]
29. Molecular pathogenesis of uterine smooth muscle tumors from transcriptional profiling.
Quade BJ; Wang TY; Sornberger K; Dal Cin P; Mutter GL; Morton CC
Genes Chromosomes Cancer; 2004 Jun; 40(2):97-108. PubMed ID: 15101043
[TBL] [Abstract][Full Text] [Related]
30. Prognostic significance of bcl-2 expression in leiomyosarcoma of the uterus.
Zhai YL; Nikaido T; Toki T; Shiozawa A; Orii A; Fujii S
Br J Cancer; 1999 Jul; 80(10):1658-64. PubMed ID: 10408415
[TBL] [Abstract][Full Text] [Related]
31. Comparison of chromosome aberrations in leiomyoma and leiomyosarcoma using FISH on archival tissues.
Han K; Lee W; Harris CP; Simsiman RC; Lee K; Kang C; Meisner LF
Cancer Genet Cytogenet; 1994 May; 74(1):19-24. PubMed ID: 8194042
[TBL] [Abstract][Full Text] [Related]
32. Deletions of chromosome 13q, mutations in Retinoblastoma 1, and retinoblastoma protein state in human hepatocellular carcinoma.
Zhang X; Xu HJ; Murakami Y; Sachse R; Yashima K; Hirohashi S; Hu SX; Benedict WF; Sekiya T
Cancer Res; 1994 Aug; 54(15):4177-82. PubMed ID: 8033150
[TBL] [Abstract][Full Text] [Related]
33. Clinical Benefit in Response to Palbociclib Treatment in Refractory Uterine Leiomyosarcomas with a Common
Elvin JA; Gay LM; Ort R; Shuluk J; Long J; Shelley L; Lee R; Chalmers ZR; Frampton GM; Ali SM; Schrock AB; Miller VA; Stephens PJ; Ross JS; Frank R
Oncologist; 2017 Apr; 22(4):416-421. PubMed ID: 28283584
[TBL] [Abstract][Full Text] [Related]
34. Rearrangement of band 10q22 in leiomyoma and leiomyosarcoma of the uterus.
Kiechle-Schwarz M; Berger CS; Surti U; Sandberg AA
Cancer Genet Cytogenet; 1990 Jul; 47(1):95-100. PubMed ID: 2357691
[TBL] [Abstract][Full Text] [Related]
35. Frequent occurrence of uniparental disomy in colorectal cancer.
Andersen CL; Wiuf C; Kruhøffer M; Korsgaard M; Laurberg S; Ørntoft TF
Carcinogenesis; 2007 Jan; 28(1):38-48. PubMed ID: 16774939
[TBL] [Abstract][Full Text] [Related]
36. Comparative immunohistochemical and molecular analysis of uterine and extrauterine leiomyosarcomas.
Rao UN; Finkelstein SD; Jones MW
Mod Pathol; 1999 Nov; 12(11):1001-9. PubMed ID: 10574596
[TBL] [Abstract][Full Text] [Related]
37. Bi-allelic inactivation is more prevalent at relapse in multiple myeloma, identifying RB1 as an independent prognostic marker.
Chavan SS; He J; Tytarenko R; Deshpande S; Patel P; Bailey M; Stein CK; Stephens O; Weinhold N; Petty N; Steward D; Rasche L; Bauer M; Ashby C; Peterson E; Ali S; Ross J; Miller VA; Stephens P; Thanendrarajan S; Schinke C; Zangari M; van Rhee F; Barlogie B; Mughal TI; Davies FE; Morgan GJ; Walker BA
Blood Cancer J; 2017 Feb; 7(2):e535. PubMed ID: 28234347
[TBL] [Abstract][Full Text] [Related]
38. Uterine leiomyosarcomas are characterized by high p16, p53 and MIB1 expression in comparison with usual leiomyomas, leiomyoma variants and smooth muscle tumours of uncertain malignant potential.
O'Neill CJ; McBride HA; Connolly LE; McCluggage WG
Histopathology; 2007 Jun; 50(7):851-8. PubMed ID: 17543074
[TBL] [Abstract][Full Text] [Related]
39. [Benign metastatic leiomyoma of the corpus uteri].
Andreeva IuIu; Danilova NV; Shikeeva AA; Kekeeva TV; Zavalishina LE; Frank GA
Arkh Patol; 2012; 74(6):39-43. PubMed ID: 23383444
[TBL] [Abstract][Full Text] [Related]
40. MED12 and uterine smooth muscle oncogenesis: State of the art and perspectives.
Croce S; Chibon F
Eur J Cancer; 2015 Aug; 51(12):1603-10. PubMed ID: 26037152
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
